The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial
Open accessAbstract
AIMS: Thiazolidinediones are insulin sensitizers, and are associated with fluid retention and increased risk of heart failure (HF) in people with type 2 diabetes. We assessed fatal and non-fatal HF events and their outcome, and identified HF predictors in the RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycaemia in Diabetes) trial population. METHODS AND RESULTS: In a multicentre, open-label study, we randomized 4447 people with type 2 diabetes on metformin or sulfonylurea monotherapy with a mean HbA(1c) of 7.9% to add-on rosiglitazone (n = 2220) or to a combination of metformin and sulfonylurea (n = 2227) and followed them over 5.5 years on average. Heart failure hospitalizations and deaths were adjudicated by a Clinical Endpoint Committee using pre-specified criteria. Independent predictors of HF events were identified out of a group of 30 pre-specified clinical, demographic, and biological variables. In the rosiglitazone group, the risk of HF death or hospitalization was doubled: HR = 2.10 (95% CI, 1.35-3.27): the excess HF event rate was 2.6 (1.1-4.1) per 1000 person-years. An excess in HF deaths was observed (10 vs. two), including four HF deaths as first HF events. By contrast, there was no increase in cardiovascular mortality or hospitalization (HR = 0.99, 95% CI, 0.85-1.16) or in cardiovascular deaths (60 vs. 71). Independent predictors of HF were rosiglitazone assignment, age, urinary albumin : creatinine ratio, body mass index, and systolic blood pressure at baseline. A history of previous cardiovascular disease was not predictive of HF. Duration of HF hospitalization and rate of HF re-hospitalization were similar in the two groups. CONCLUSION: These findings confirm the increased risk of HF events in people treated with rosiglitazone and support the recommendation that this agent should not continue to be used in people developing symptomatic HF while using the medication. Close follow-up for the risk of HF should be offered to elderly people, people with markedly increased body mass index, people with microalbuminuria/proteinuria, and people with increased systolic blood pressure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the RECORD 112 and the PROactive trials, 183 patients randomized to TZDs, rosiglitazone and pioglitazone, respectively, had more HF events than those on placebo.”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [112]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Guidelines for the diagnosis and treatment of chronic heart failure
Remme, W. J. (2001) · European Heart Journal · doi:10.1053/euhj.2001.2783 · Cited by 1,595
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60953-3 · Cited by 1,393
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure
Nesto, R. W., Bell, D. S. H., Bonow, R. O., Fonseca, V. A., Grundy, S. M., Horton, E. S., Winter, M. L., Porte, D., Semenkovich, C. F., Smith, S. E., et al. (2003) · Circulation · doi:10.1161/01.cir.0000103683.99399.7e · Cited by 831
Lago, R. M., Singh, P. P., & Nesto, R. W. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61514-1 · Cited by 710
Glycemic Control and Heart Failure Among Adult Patients With Diabetes
Iribarren, C., Karter, A. J., Go, A. S., Ferrara, A. M., Liu, J. Y., Sidney, S., & Selby, J. V. (2001) · Circulation · doi:10.1161/01.cir.103.22.2668 · Cited by 709
Guan, Y., Hao, C., Cha, D. R., Rao, R., Lu, W., Kohan, D. E., Magnuson, M. A., Redha, R., Zhang, Y., & Breyer, M. D. (2005) · Nature Medicine · doi:10.1038/nm1278 · Cited by 608
Research works printed but not linked: 1
- 2001, Diabetes Care, 24, 614
Cited by
Sorted by citations
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2021) · PubMed · doi:10.1093/eurheartj/ehab670 · Cited by 20,604
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Self-citation2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs105 · Cited by 2,644
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M. L., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T. B., Januzzi, J. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31829e8776 · Cited by 2,234
Seferović, P. M., Petrie, M. C., Filippatos, G. S., Anker, S. D., Rosano, G., Bauersachs, J., Paulus, W. J., Komajda, M., Cosentino, F., de Boer, R. A., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1170 · Cited by 708
Self-citationEzekowitz, J. A., O'Meara, E., McDonald, M. A., Abrams, H., Chan, M., Ducharme, A., Giannetti, N., Grzeslo, A., Hamilton, P. G., Heckman, G. A., et al. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.08.022 · Cited by 676
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000691 · Cited by 639
Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction
Mentz, R. J., Kelly, J. P., von Lueder, T. G., Voors, A. A., Lam, C. S. P., Cowie, M. R., Kjeldsen, K., Jankowska, E. A., Atar, D., Butler, J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.08.036 · Cited by 546
Bozkurt, B., Aguilar, D. A., Deswal, A. M., Dunbar, S. B., Francis, G. S., Horwich, T. B., Jessup, M. L., Kosiborod, M., Pritchett, A. M., Ramasubbu, K., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000450 · Cited by 556
Drugs That May Cause or Exacerbate Heart Failure
Page, R. L., II, O’Bryant, C. L., Cheng, D., Dow, T. J., Ky, B., Stein, C. M., Spencer, A. P., Trupp, R. J., & Lindenfeld, J. M. (2016) · Circulation · doi:10.1161/cir.0000000000000426 · Cited by 495
McMurray, J. J. V., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Bengtsson, O., Ponikowski, P., Sabatine, M. S., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1432 · Cited by 433
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P. P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González‐Juanatey, J. R., Harjola, V., Jankowska, E. A., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0141 · Cited by 458
Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019
Précoma, D. B., de Oliveira, G. M. M., Simão, A. F. L., Dutra, Ó. P., Coelho-Filho, O. R., Izar, M. C. D. O., Póvoa, R., Giuliano, I. D. C. B., Filho, A. C. D. A., Machado, C. A., et al. (2019) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20190204 · Cited by 507
2020 Clinical practice guidelines for Chronic heart failure
Russian Society of Cardiology (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-4083 · Cited by 553
Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda
Rohde, L. E. P., Montera, M. W., Bocchi, E. A., Clausell, N., de Albuquerque, D. C., Rassi, S., Colafranceschi, A. S., Freitas, A. F., Ferraz, A. S., Biolo, A., et al. (2018) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20180190 · Cited by 492
Kristensen, S. L., Preiss, D., Jhund, P. S., Squire, I., Cardoso, J. S., Merkely, B., Martinez, F., Starling, R. C., Desai, A. S., Lefkowitz, M. P., et al. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002560 · Cited by 359
Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored
McMurray, J. J. V., Gerstein, H. C., Holman, R. R., & Pfeffer, M. A. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70031-2 · Cited by 305
Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy
Gilbert, R. E., & Krum, H. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61402-1 · Cited by 303
Maack, C., Lehrke, M., Backs, J., Heinzel, F. R., Hulot, J., Marx, N., Paulus, W. J., Rossignol, P., Taegtmeyer, H., Bauersachs, J. K., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy596 · Cited by 255
Relevance of Molecular Docking Studies in Drug Designing
Jakhar, R., Dangi, M., Khichi, A., & Chhillar, A. K. (2019) · Current Bioinformatics · doi:10.2174/1574893615666191219094216 · Cited by 218
2024 Clinical practice guidelines for Chronic heart failure
Galyavich, A. S., Tereshchenko, S. N., Uskach, T. M., Ageev, F. T., Aronov, D. M., Arutyunov, G. P., Begrambekova, Y. L., Belenkov, Y. N., Boytsov, S. A., Bubnova, M. G., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6162 · Cited by 251
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0002 · Cited by 275
Castagno, D., Baird-Gunning, J., Jhund, P. S., Biondi‐Zoccai, G., MacDonald, M. R., Petrie, M. C., Gaïta, F., & McMurray, J. J. V. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.07.030 · Cited by 189
Seferovic, P. M., Coats, A. J. S., Ponikowski, P. P., Filippatos, G. S., Huelsmann, M., Jhund, P. S., Polovina, M. M., Michel Komajda, N., Seferović, J. P., Sarı, İ., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1673 · Cited by 183
Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
Lorenz, M., Lawson, F., Owens, D., Raccah, D., Roy-Duval, C., Lehmann, A., Perfetti, R., & Blonde, L. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0490-6 · Cited by 166
McMurray, J. J. V., Ponikowski, P., Bolli, G. B., Lukashevich, V., Kozlovski, P., Kothny, W., Lewsey, J. D., & Krum, H. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2017.08.004 · Cited by 165
Udell, J. A., Bhatt, D. L., Braunwald, E., Cavender, M. A., Mosenzon, O., Steg, P. G., Davidson, J. A., Nicolau, J. C., Corbalan, R. L., Hirshberg, B., et al. (2014) · Diabetes Care · doi:10.2337/dc14-1850 · Cited by 163
Targeting mitochondrial oxidative metabolism as an approach to treat heart failure
Fillmore, N., & Lopaschuk, G. D. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.08.014 · Cited by 146
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.05.007 · Cited by 145
García‐Ropero, Á., Badimón, J. J., & Santos‐Gallego, C. G. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1551877 · Cited by 150
Atualização da Diretriz Brasileira de Insuficiência Cardíaca Crônica - 2012
Bocchi, E., Marcondes‐Braga, F. G., Bacal, F., Ferraz, A., Albuquerque, D., & Rodrigues, D. (2012) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2012001000001 · Cited by 142
Sandesara, P. B., O’Neal, W. T., Kelli, H. M., Samman-Tahhan, A., Hammadah, M., Quyyumi, A. A., & Sperling, L. S. (2018) · Diabetes Care · doi:10.2337/dc17-0755 · Cited by 130
Lee, M. M. Y., McMurray, J. J. V., Lorenzo-Almorós, A., Kristensen, S. L., Sattar, N. A., Jhund, P. S., & Petrie, M. C. (2018) · Heart · doi:10.1136/heartjnl-2016-310342 · Cited by 121
Marso, S. P., Baeres, F. M. M., Bain, S. C., Goldman, B., Husain, M., Nauck, M. A., Poulter, N. R., Pratley, R. E., Thomsen, A. B., & Buse, J. B. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.12.063 · Cited by 118
Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future
Davidson, M., Mattison, D. R., Azoulay, L., & Krewski, D. R. (2017) · Critical Reviews in Toxicology · doi:10.1080/10408444.2017.1351420 · Cited by 117
Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy
Wang, L., Cai, Y., Jian, L., Cheung, C. W., Zhang, L., & Xia, Z. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01188-0 · Cited by 116
Kowaltowski, A. J., & Abdulkader, F. (2020) · Springer eBooks · doi:10.1007/978-3-030-50968-2_9 · Cited by 106
Chartoumpekis, D. V., & Kensler, T. W. (2013) · Current Diabetes Reviews · doi:10.2174/1573399811309020005 · Cited by 105
Heart Failure Outcomes in Clinical Trials of Glucose-Lowering Agents in Patients with Diabetes
FITCHETT, D. H., Udell, J. A., & Inzucchi, S. E. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.633 · Cited by 102
Myocardial Energy Substrate Metabolism in Heart Failure : from Pathways to Therapeutic Targets
Fukushima, A., Milner, K., Gupta, A. K., & Lopaschuk, G. D. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150710150445 · Cited by 98
Seferovic, P. M., Paulus, W. J., Rosano, G., Polovina, M. M., Petrie, M. C., Jhund, P. S., Tschöpe, C., Sattar, N. A., Piepoli, M. F., Papp, Z. L., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3347 · Cited by 107
The rise and fall of rosiglitazone
Nissen, S. E. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq016 · Cited by 91
Diabetic cardiomyopathy: Pathophysiology, theories and evidence to date
Athithan, L., Gulsin, G. S., McCann, G. P., & Levelt, E. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i10.490 · Cited by 93
2020 Clinical practice guidelines for Chronic heart failure
Russian Society of Cardiology (2020) · Russian Journal of Cardiology · doi:10.15829/29/1560-4071-2020-4083 · Cited by 88
Li, P., Chen, Y., Liu, J., Hong, J., Deng, Y., Yang, F., Xiu-ping, J., Gao, J. S., Li, J., Fang, H., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126027 · Cited by 89
Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond
Martens, P., Mathieu, C., & Verbrugge, F. H. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0522-x · Cited by 88
Bilan, V. P., Salah, E., Bastacky, S., Jones, H. B., Mayers, R. M., Zinker, B. A., Poucher, S. M., & Tofovic, S. P. (2011) · Journal of Endocrinology · doi:10.1530/joe-11-0122 · Cited by 86
EMPA-REG – the “diuretic hypothesis”
McMurray, J. J. V. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.10.012 · Cited by 83
Joubert, M., Manrique, A., Cariou, B., & Prieur, X. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.07.003 · Cited by 81
DePaoli, A. M., Higgins, L. S., Henry, R. R., Mantzoros, C. S., & Dunn, F. L. (2014) · Diabetes Care · doi:10.2337/dc13-2480 · Cited by 81
Yamada, H., Tanaka, A., Kusunose, K., Amano, R., Matsuhisa, M., Daida, H., Ito, M., Tsutsui, H., Nanasato, M., Kamiya, H., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0546-2 · Cited by 76
Marder, W., Khalatbari, S. H., Myles, J. D., HENCH, R. P., Lustig, S., Yalavarthi, S., Parameswaran, A., Brook, R. D., & Kaplan, M. J. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000441 · Cited by 77
Korean Guidelines for Diagnosis and Management of Chronic Heart Failure
Kim, M., Lee, J., Kim, E. J., Park, D.-G., Park, S., Park, J. J., Shin, M., Yoo, B., Youn, J., Lee, S. E., et al. (2017) · Korean Circulation Journal · doi:10.4070/kcj.2017.0009 · Cited by 76
Cardiac Insulin Resistance in Heart Failure: The Role of Mitochondrial Dynamics
Saotome, M., Ikoma, T., Hasan, P., & Maekawa, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143552 · Cited by 71
Effect of Glucose Levels on Cardiovascular Risk
Poznyak, A. V., Litvinova, L. S., Poggio, P., Sukhorukov, V. N., & Orekhov, A. N. (2022) · Cells · doi:10.3390/cells11193034 · Cited by 76
Labute, M. X., Zhang, X., Lenderman, J., Bennion, B. J., Wong, S., & Lightstone, F. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106298 · Cited by 66
Lorenzo-Almorós, A., Cepeda-Rodrigo, J. M., & Lorenzo, Ó. (2020) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2019.10.012 · Cited by 74
Varas‐Lorenzo, C., Margulis, A. V., Pladevall, M., Riera‐Guàrdia, N., Calingaert, B., Hazell, L., Romio, S., & Perez‐Gutthann, S. (2014) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-14-129 · Cited by 67
Bach, R. G., Brooks, M. M., Lombardero, M., GENUTH, S. M., Donner, T. W., Garber, A. J., Kennedy, L., Monrad, E. S., Pop‐Busui, R., Kelsey, S. F., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.000678 · Cited by 65
Piepoli, M. F., Adamo, M., Barison, A., Bestetti, R. B., Biegus, J., Böhm, M., Butler, J., Carapetis, J. R., Ceconi, C., Chioncel, O. D., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2351 · Cited by 73
An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes
Giglio, R. V., Παπάνας, Ν., Rizvi, A. A., Ciaccio, M., Patti, A. M., Ilias, Ι., Stoian, A. P., Sahebkar, A., Janež, A., & Rizzo, M. (2022) · Medicina · doi:10.3390/medicina58101475 · Cited by 72
Rotkvić, P. G., Planinić, Z., Pršo, A.-M. L., Šikić, J., Galić, E., & Rotkvić, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115973 · Cited by 64
Wang, C., Chen, C., Lin, M.-H., Su, H., Ho, M.-Y., Yeh, J., Tsai, M., Hsieh, C., & Wen, M. (2020) · Biology · doi:10.3390/biology9110369 · Cited by 63
Comorbidities in Heart Failure
van der Wal, H. H., van Deursen, V. M., van der Meer, P., & Voors, A. A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_27 · Cited by 63
Targeting metabolic disturbance in the diabetic heart
Fuentes‐Antrás, J., Picatoste, B., Ramírez, E., Egido, J., Tuñón, J., & Lorenzo, Ó. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0173-8 · Cited by 60
Cardiovascular risk and thiazolidinediones—what do meta‐analyses really tell us?
Schernthaner, G.-H., & CHILTON, R. J. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01262.x · Cited by 57
Diabetes mellitus type 2 in adults
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Шамхалова, М. Ш., Sukhareva, O. Y., Galstyan, G. R., Tokmakova, A. Y., Nikonova, T. V., Surkova, E. V., Кононенко, И. В., et al. (2020) · Diabetes Mellitus · doi:10.14341/dm12507 · Cited by 60
Loke, Y. K., Golder, S. P., & Vandenbroucke, J. P. (2011) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098611401129 · Cited by 49
Treatment of type 2 diabetes patients with heart conditions
Aktaş, G., Tel, B. M. A., Tel, M. R., & Balci, B. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2204941 · Cited by 49
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 58
Wang, Y., Negishi, T., Negishi, K., & Marwick, T. H. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.01.011 · Cited by 46
Chang, Y., Chen, Y., Huang, C.-W., Fan, S.-C., Huang, B., Chang, W., Tsai, Y.-S., Su, F., & Wu, C. (2016) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2016.00027 · Cited by 43
PPARs in the Renal Regulation of Systemic Blood Pressure
Rőszer, T., & Ricote, M. (2010) · PPAR Research · doi:10.1155/2010/698730 · Cited by 42
Risk of Stroke with Thiazolidinediones: A Ten-Year Nationwide Population-Based Cohort Study
Lu, C.-J., Sun, Y., Muo, C., Chen, R.-C., Chen, P., & Hsu, C. Y. (2013) · Cerebrovascular Diseases · doi:10.1159/000353679 · Cited by 41
Madsen, K. S., Kähler, P., Kähler, L. K. A., Madsbad, S., Gnesin, F., Metzendorf, M., Richter, B., & Hemmingsen, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012368.pub2 · Cited by 43
The AHA/ACC/HFSA 2022 Heart Failure Guidelines: Changing the Focus to Heart Failure Prevention
Abovich, A., Matasic, D. S., Cardoso, R. N., Ndumele, C. E., Blumenthal, R. S., Blankstein, R., & Gulati, M. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100527 · Cited by 44
Pfister, R., Cairns, R., Erdmann, E., & Schneider, C. A. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.05.056 · Cited by 40
Hu, S., Tian, Y., Chang, Y., Li, Z., Xue, C., & Wang, Y. (2014) · Journal of Medicinal Food · doi:10.1089/jmf.2013.2924 · Cited by 39
Nasir, S., & Aguilar, D. A. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.031 · Cited by 39
Bioengineering Beige Adipose Tissue Therapeutics
Tharp, K. M., & Stahl, A. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00164 · Cited by 40
Piepoli, M. F., Adamo, M., Barison, A., Bestetti, R. B., Biegus, J., Böhm, M., Butler, J., Carapetis, J. R., Ceconi, C., Chioncel, O. D., et al. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab147 · Cited by 43
Outcomes and lessons from the PROactive study
Scheen, A. J. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.09.001 · Cited by 37
Yang, J. P.-W., Anderson, A. E., McCartney, A. M., Ory, X., Ma, G., Pappalardo, E., Bader, J. S., & Elisseeff, J. H. (2017) · Tissue Engineering Part A · doi:10.1089/ten.tea.2016.0399 · Cited by 39
McMurray, J. J. V., Adamopoulos, S. N., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G. S., Fonseca, C., Sánchez, M. Á. G., et al. (2012) · Revista Española de Cardiología · doi:10.1016/j.recesp.2012.08.003 · Cited by 36
Does Thiazolidinedione therapy exacerbate fluid retention in congestive heart failure?
Goltsman, I., Khoury, E. E., Winaver, J. M., & Abassi, Z. A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.09.007 · Cited by 33
Incretins as a novel therapeutic strategy in patients with diabetes and heart failure
Khan, M. A., Deaton, C., Rutter, M. K., Neyses, L., & Mamas, M. A. (2012) · Heart Failure Reviews · doi:10.1007/s10741-012-9318-y · Cited by 32
Management of Noncardiac Comorbidities in Chronic Heart Failure
Chong, V., Singh, J. S., Parry, H., Saunders, J., Chowdhury, F., MANCINI, D. M., & Lang, C. C. (2015) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12141 · Cited by 35
Hadidi, S. E., Rosano, G. M. C., Tamargo, J. L., Agewall, S., Drexel, H., Kaski, J. C., Niessner, A., Lewis, B. S., Coats, A. J. S., & Savarese, G. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa108 · Cited by 32
Chiang, C., Ueng, K.-C., Chao, T., Lin, T., Wu, Y.-J., Wang, K.-L., Sung, S., Yeh, H., Li, Y., Liu, P., et al. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000359 · Cited by 30
PPARγ activator, rosiglitazone: Is it beneficial or harmful to the cardiovascular system?
Palee, S. (2011) · World Journal of Cardiology · doi:10.4330/wjc.v3.i5.144 · Cited by 29
Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus
Sharma, A., Cooper, L. B., Fiuzat, M., Mentz, R. J., Ferreira, J. P., Butler, J., FITCHETT, D. H., Moses, A. C., O’Connor, C. J., & Zannad, F. M. (2018) · JACC Heart Failure · doi:10.1016/j.jchf.2018.05.020 · Cited by 29
Contemporary Management of Heart Failure in Patients With Diabetes
Shaw, J. A., & Cooper, M. E. (2020) · Diabetes Care · doi:10.2337/dc20-2173 · Cited by 29
Patel, D. B., Walitt, B. T., Lindsay, J. M., & Wilensky, R. L. (2011) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2010.10.016 · Cited by 29
Galougahi, K. K., Liu, C., Garcia, A., Fry, N. A. S., Hamilton, E. J., Figtree, G. A., & Rasmussen, H. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00071.2015 · Cited by 30
Lorenzo-Almorós, A., Cepeda-Rodrigo, J. M., & Lorenzo, Ó. (2020) · Revista Clínica Española · doi:10.1016/j.rce.2019.10.013 · Cited by 31
Metadata
- Authors
- Komajda, M., McMurray, J. J. V., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Pocock, S. J., Curtis, P. S., Jones, N. P., & Home, P. D.
- Affiliations
- University of Glasgow (GB)
- Universitat de Barcelona (ES)
- London School of Hygiene & Tropical Medicine (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- Newcastle University (GB)
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-01-29
- Volume
- 31
- Issue
- 7
- Pages
- 824-831
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- PMC
- PMC2848325
- OpenAlex
- W2115360698
- Cited by
- 234
- References
- 27
- Citations by year
- 2026: 7 · 2025: 5 · 2024: 7 · 2023: 6 · 2022: 10 · 2021: 15 · 2020: 24 · 2019: 17 · 2018: 14 · 2017: 19 · 2016: 16 · 2015: 20 · 2014: 19 · 2013: 10 · 2012: 17
- FWCI
- 13.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- other-oa
- Locations
- European Heart Journal (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- GlaxoSmithKline
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- rosiglitazone, heart failure, type 2 diabetes, thiazolidinediones, heart failure hospitalization, heart failure mortality, risk factors, metformin, sulfonylureas, urinary albumin-creatinine ratio, body mass index, systolic blood pressure, cardiovascular mortality, RECORD trial, insulin sensitizers, fluid retention, microalbuminuria
- MeSH terms
- Rosiglitazone, Adult, Aged, Diabetes Mellitus, Type 2, Female, Heart Failure, Humans, Hypoglycemic Agents, Male, Middle Aged, Risk Factors, Thiazolidinediones, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
